Moxifloxacin Struggles Against Current TB Drugs: REMox TrialMoxifloxacin Struggles Against Current TB Drugs: REMox Trial
Although a shorter, moxifloxacin-containing regimen did not measure up to standard tuberculosis therapy, the drug shows promise, experts say. Medscape Medical News
CONCLUSION: Clinicians should consider the possibility of SPN for pancreatic heterogeneous masses. Multiple diagnostic imaging modalities and EUS-FNA may contribute to the preoperative diagnosis of this disease. PMID: 32211105 [PubMed]
a Jarmila Vinšová Martin Doležal Jan Zitko According to the World Health Organization, tuberculosis is still in the top ten causes of death from a single infectious agent, killing more than 1.7 million people worldwide each year. The rising resistance developed by Mycobacterium tuberculosis against currently used antituberculars is an imperative to develop new compounds with potential antimycobacterial activity. As a part of our continuous research on structural derivatives of the first-line antitubercular pyrazinamide, we have designed, prepared, and assessed the in vitro whole cell growth inhibit...
Around the world, more than 40 teams are working on a vaccine for Covid-19. We followed one doctor in the most urgent quest of his life. By Samanth SubramanianCoronavirus – latest updatesSee all our coronavirus coverageOf the dozens of places where a coronavirus vaccine might be born, one is DIOSynVax, a small company started by a Canadian pathologist named Jonathan Heeney. In ordinary times, I ’d have visited Heeney in his office, in a stately red-brick building in Cambridge. I’d have met his team and his Aria III cytometer, which looks like as if might brew a strong, space-age espresso but which, in fac...
Conditions: Pharmaceutical Care; HIV/AIDS; Tuberculosis Intervention: Other: Pharmaceutical Care Sponsors: Bekasi City Public Hospital; University of Groningen Completed
Publication date: Available online 26 March 2020Source: Microbial PathogenesisAuthor(s): Xiaochun Jin, Shuzhou Yin, Youtao Zhang, Xu Chen
[Global Fund] The Global Fund to Fight AIDS, Tuberculosis and Malaria welcomes the Japanese Diet's passage of the fiscal 2019 supplementary budget and the fiscal 2020 budget, which includes Japan's contribution of US$476.4 million to the Global Fund in 2020. This is its largest annual contribution to the Global Fund, signaling Japan's strong leadership in global health, at a time when the world is fighting COVID-19.
[Daily News] AS the world comes together to tackle the COVID-19 pandemic, it is important to ensure that essential services and operations for dealing with long-standing health problems continue to protect the lives of people with TB and other diseases or health conditions.
[Daily News] CITY Council of Dodoma (CCD) has commended the Benjamin Mkapa Hospital (BMH) for surpassing its target to reach 60 TB patients in 2019 set by the City authorities.
[Daily News] KAGERA Region is overwhelmed by high cases of tuberculosis with limited capacity and resources for treatment and care and the situation is made worse by ignorance among the victims who report late to health centres for treatment and care.
This report summarizes data on TB symptom screening and TPT initiation and completion among ART patients in 16 countries supported by the U.S. President's Emergency Plan for AIDS† Relief (PEPFAR) during April 1, 2017-March 31, 2019. During this period, these 16 countries accounted for approximately 90% of PEPFAR-supported ART patients. During April 1, 2017-September 30, 2018, TB symptom screening increased from 54% to 84%. Overall, nearly 2 million ART patients initiated TPT, and 60% completed treatment during October 1, 2017-March 31, 2019. Although TPT initiations increased substantially, completion among those wh...